chromosome 16 open reading frame 89Genealiases: []
Q-omics provides the consensus-scored C16orf89 profile across patient tissues and cancer cell-line models. C16orf89 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, C16orf89 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, C16orf89 RNA expression shows 24,993 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KIRC, and LSCC as cancer lineages where C16orf89 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C16orf89 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C16orf89 survival associations across molecular data types. C16orf89 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C16orf89 RNA expression–survival associations across cancer types. High C16orf89 expression shows unfavorable associations in BLCA, KIRP, UVM and LUSC, but favorable associations in CHOL and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for C16orf89 RNA expression.
This table summarizes C16orf89 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C16orf89. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C16orf89 shows lower tumor expression in KIRC, BLCA, KIRP, THCA, COAD and HNSC. The KIRC box plot shows higher C16orf89 RNA expression in normal versus tumor tissue (log2 FC = −3.573, t-test p < 0.001).
This table shows molecular features associated with C16orf89 in patient tissues and cancer cell lines. In patient samples, C16orf89 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C16orf89 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
